Want to see CBLL full AI Analyst Report?
CBLL Stock Chart & Stats
$18.36
-$0.15(-0.64%)
At close: 4:00 PM EST
$18.36
-$0.15(-0.64%)
Day’s Range― - ―
52-Week Range$10.85 - $24.33
Previous CloseN/A
Volume46.56K
Average Volume (3M)265.67K
Market Cap
$736.09M
Enterprise Value$632.51M
Total Cash (Recent Filing)$141.18M
Total Debt (Recent Filing)$22.12M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 11, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding37,942,700
10 Day Avg. Volume244,220
30 Day Avg. Volume265,666
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue6.65
Enterprise Value/Gross Profit7.59
Enterprise Value/Ebitda-11.04
Forecast
1Y Price Target
$28.50Price Target Upside55.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$113.99M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & High Gross MarginsConsistent rapid revenue growth combined with persistently high gross margins (~84–88%) signals durable product-market fit and strong unit economics. High gross margins create long-term pricing power and margin cushion as the company scales, supporting sustained reinvestment into commercial and product expansion.
Commercial Traction And Utilization GrowthExpanding hospital footprint and record headband utilization indicate durable clinical adoption and rising recurring/consumable revenue. Broader acute-care penetration increases referenceability, supports upsell of subscriptions and consumables, and builds predictable per-account lifetime value as deployments become standard of care.
Solid Liquidity PositionA cash balance of $141.2M provides meaningful runway to fund commercialization, regulatory activities, and product launches. Combined with manageable reported debt levels, this liquidity supports multi-quarter execution on growth initiatives and reimbursement efforts without immediate refinancing pressure.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicate the business requires ongoing external funding to sustain growth. Persistent cash burn reduces financial flexibility, raises dilution risk for shareholders, and means execution depends on maintaining fundraising access until operations move to cash neutrality.
Deep Negative Net MarginsA ~-64% net margin and widening quarterly losses show profitability is distant despite revenue gains. Deep negative margins depress returns on invested capital, increase dependency on external capital, and signal the need for substantial operating leverage or structural cost reductions to achieve sustainable profitability.
Rising Operating Expenses And Litigation CostsSignificantly higher operating expenses and elevated IP litigation costs materially increase near-term burn and complicate the path to breakeven. Persistent elevated OpEx or recurring litigation spend can erode runway, divert management focus from commercial execution, and delay the realization of operating leverage.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $24.33 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $736.09M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 33 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on May 11, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.129.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,942,700 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went down -16.5%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (55.23% Upside)
$28.50 (55.23% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.74%
12-Months-Change
Fundamentals
Return on Equity
-38.19%
Trailing 12-Months
Asset Growth
-16.58%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
CBLL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and robust top-line growth (29% YoY revenue, record account additions, high 87% gross margin), alongside several strategic milestones (neonate/pediatric launches, delirium pilot with FDA clearance, favorable NTAP proposal, LVO Breakthrough designation) and a healthy cash position. Offsetting these positives are elevated operating expenses (+36% YoY), significant near-term litigation costs ($5.6M in Q1), a wider net loss ($19.7M), and continued adjusted EBITDA losses. Given the combination of accelerating revenue/market expansion and manageable but notable near-term expense pressures, the tone is constructive with near-term investment-driven profitability headwinds.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$28.50
▲(55.23% Upside)
Technical Analysis
Ownership Overview
26.46% Insiders
25.95% Mutual Funds
<0.01% Other Institutional Investors
39.89% Public Companies and
Individual Investors